The co-founders of BioNTech, married couple, Professors Ugur Sahin and Özlem Türec, today (10 March) announced plans to step down from BioNTech leadership roles and establish an independent company to develop next-generation mRNA innovations with disruptive potential. Sahin and Türeci will transition to managing their new company by the end of 2026.
BioNTech will continue to focus on its late-stage pipeline spanning innovative immunomodulator, antibody-drug conjugate (“ADC”), mRNA candidates and its COVID-19 vaccine franchise. BioNTech has 15 ongoing Phase 3 clinical trials in oncology.
“Over the past 18 years, we have built BioNTech from a start-up into a global biopharmaceutical company with a strong and diversified pipeline. During…
